References
- Akerley W, Herndon JE, Egorin MJ, et al (2003). Weekly, highdose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the cancer and leukemia group B. Cancer, 97, 2480-6. https://doi.org/10.1002/cncr.11375
- Anonymous (1995). Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. non-small cell lung cancer collaborative group. BMJ, 311, 899-909. https://doi.org/10.1136/bmj.311.7010.899
- Biedermann B, Landmann C, Kann R, et al (2000). Combined chemoradiotherapy with daily low-dose cisplatin in locally advanced inoperable non-small cell lung cancer. Radiother Oncol, 56, 169-73. https://doi.org/10.1016/S0167-8140(00)00203-6
- Camps C, Massuti B, Jimenez A, et al (2006). Randomized phase IIIstudy of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish lung cancer group trial. Ann Oncol, 17, 467-72. https://doi.org/10.1093/annonc/mdj115
- Chang AY, Rubins J, Asbury R, et al (2001). Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol, 28, 10-3.
- Chen CH, Chang J W, Lee CH, et al (2005). Dose-finding and phase 2 study of weekly paclitaxel (Taxol) and cisplatin combination in treating Chinese patients with advanced nonsmall cell lung cancer. Am J Clin Oncol, 28, 508-12. https://doi.org/10.1097/01.coc.0000182419.47882.51
- Cheng AM, Wood DE (2011). Surgical and endoscopic palliation of advanced lung cancer. Surg Oncol Clin N Am, 20, 779-90. https://doi.org/10.1016/j.soc.2011.07.008
- European organization for research and treatment of cancer (2000). Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. Eur J Cancer, 36, 592-600. https://doi.org/10.1016/S0959-8049(99)00315-9
- Gauden S, Ramsay J, Tripeony L (1995). The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest, 108, 1278-82. https://doi.org/10.1378/chest.108.5.1278
- Goldstraw P, Crowley J, Chansky K, et al (2007). International association for the study of lung cancer international staging committee: participating institutions. J Thorac Oncol, 2, 706-14. https://doi.org/10.1097/JTO.0b013e31812f3c1a
- Greco FA (1999). Docetaxel (Taxotere) administrated in weekly schedules. Semin Oncol, 26, 28-31.
- Hainsworth JD, Burris HA 3rd, Erland JB, et al (1998). Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. Clin Oncol, 16, 2164-8.
-
Jatoi A, Stella PJ, Hillman S, et al (2003). Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (
${\geq}$ 65 years of age): a phase II north central cancer treatment group study. Am J Clin Oncol, 26, 441-7. https://doi.org/10.1097/01.coc.0000027460.53907.38 - Kaira K, Takise A, Minato K, et al (2005). Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anticancer Drugs, 16, 455-60. https://doi.org/10.1097/00001813-200504000-00013
- Luchtenborg M, Jakobsen E, Krasnik M, et al (2012). The effect of comorbidity on stage-specific survival in resected nonsmall cell lung cancer patients. Eur J Cancer, 48, 3386-95. https://doi.org/10.1016/j.ejca.2012.06.012
- Nieder C, Tollali T, Dalhaug A, et al (2014). Active anticancer treatment during the final month of life in patients with non-small cell lung cancer. Anticancer Res, 34, 1015-20.
- Pujol JL, Paz-Ares L, de Marinis F, et al (2014). Longterm and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer, 15, 418-25. https://doi.org/10.1016/j.cllc.2014.06.007
- Lester JF, Agulnik J, Akerborg O, et al (2013). What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients? results from the lung cancer economics and outcomes research (LUCEOR) study. Lung Cancer, 82, 128-35. https://doi.org/10.1016/j.lungcan.2013.06.023
- Li CH, Liu MY, Liu W, Li DD et al (2014). Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 731-6. https://doi.org/10.7314/APJCP.2014.15.2.731
- Natukula K, Jamil K, Pingali UR, et al (2013). Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. Asian Pac J Cancer Prev, 14, 4661-6. https://doi.org/10.7314/APJCP.2013.14.8.4661
- Non-small cell lung cancer collaborative group (1995). Chemotherapy in non-small cell lung cancer: A metaanalysis using updated data on individual patients from 52 randomised controlled trial. BMJ, 311, 899-909. https://doi.org/10.1136/bmj.311.7010.899
- Noronha V, Patil VM, Joshi A, Prabhash K (2013). Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer. Indian J Cancer, 50, 122-7. https://doi.org/10.4103/0019-509X.117032
- Ramalingam SS, Dahlberg SE, Langer CJ, et al (2008). Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group trial 4599. Clin Oncol, 26, 60-5. https://doi.org/10.1200/JCO.2007.13.1144
- Schaake-Koning C, van den Bogaert W, Dalesio O, et al (1992). Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med, 326, 524-30. https://doi.org/10.1056/NEJM199202203260805
- Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
- Simon TG, Beland MD, Machan JT, Dipetrillo T, Dupuy DE (2012). Charlson comorbidity index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation. Eur J Radiol, 81, 4167-72. https://doi.org/10.1016/j.ejrad.2012.06.007
- Spiro SG, Rudd RM, Souhami RL, et al (2004). Chemotherapy versus supportive care in advanced non-small cell lung cancer: Improved survival without detriment to quality of life. Thorax, 59, 828-36. https://doi.org/10.1136/thx.2003.020164
- Tsunoda T, Koizumi T, Hayasaka M, et al (2004). Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol, 54, 173-7.
- Zhou JN, Huang XE, Ye Z, Li C, et al (2009). Weekly paclitaxel/docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
Cited by
- Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4147